EVLO Evelo Biosciences, Inc. Stock Quote

EVLO [NASD]

Index	-	P/E	-	EPS (ttm)	-2.51	Insider Own	0.52%	Shs Outstand	46.17M	Perf Week	5.76%
Market Cap	641.32M	Forward P/E	-	EPS next Y	-1.77	Insider Trans	6.47%	Shs Float	42.89M	Perf Month	46.44%
Income	-87.20M	PEG	-	EPS next Q	-0.50	Inst Own	87.50%	Short Float	4.66%	Perf Quarter	159.02%
Sales	-	P/S	-	EPS this Y	-39.70%	Inst Trans	0.00%	Short Ratio	6.09	Perf Half Y	241.09%
Book/sh	1.09	P/B	12.64	EPS next Y	19.90%	ROA	-88.80%	Target Price	15.50	Perf Year	229.67%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-159.20%	52W Range	3.01 - 14.25	Perf YTD	13.98%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	4.53%	Beta	-
Dividend %	-	Quick Ratio	6.20	Sales past 5Y	-	Gross Margin	-	52W Low	394.85%	ATR	1.26
Employees	98	Current Ratio	6.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	72.16	Volatility	8.79% 12.48%
Optionable	No	Debt/Eq	0.59	EPS Q/Q	32.80%	Profit Margin	-	Rel Volume	0.46	Prev Close	13.78
Shortable	Yes	LT Debt/Eq	0.59	Earnings	Oct 29 BMO	Payout	-	Avg Volume	328.29K	Price	14.90
Recom	2.40	SMA20	25.87%	SMA50	86.99%	SMA200	176.34%	Volume	121,664	Change	8.09%

Dec-23-20

Initiated

JMP Securities

Mkt Outperform

$27

May-21-20

Downgrade

Morgan Stanley

Overweight → Equal-Weight

May-12-20

Downgrade

Jefferies

Buy → Hold

$18 → $6

Apr-30-19

Initiated

Jefferies

Buy

$18

Jan-29-19

Initiated

Chardan Capital Markets

Neutral

$10

Jan-07-21 07:00AM	Evelo Biosciences Expands Clinical Programs and Provides 2021 Guidance on Key Milestones GlobeNewswire +5.34%
Dec-23-20 10:07AM	Benzinga's Top Upgrades, Downgrades For December 23, 2020 Benzinga
Dec-21-20 07:00AM	Evelo Biosciences Appoints Industry Veteran Jonathan Zung, Ph.D. as Chief Development Officer GlobeNewswire
Dec-14-20 11:21PM	Insider Buying: The Evelo Biosciences, Inc. (NASDAQ:EVLO) Independent Chairman Just Bought 77% More Shares Simply Wall St. +24.80%
Dec-09-20 09:00AM	Evelo Biosciences Announces New Clinical Candidate in Oncology and Presents Additional Interim Data from Phase 1/2 Clinical Trial of EDP1503 in Patients with Triple-Negative Breast Cancer GlobeNewswire +22.33%
07:00AM	Evelo Biosciences Reports Positive Topline Clinical Data in Phase 1b Trial of EDP1815 in Atopic Dermatitis GlobeNewswire
Dec-03-20 07:00AM	Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of Psoriasis GlobeNewswire
Nov-27-20 10:47AM	Hedge Funds Are Dumping Evelo Biosciences, Inc. (EVLO) Insider Monkey
Nov-10-20 09:41AM	What You Need To Know About Evelo Biosciences, Inc.'s (NASDAQ:EVLO) Investor Composition Simply Wall St.
Nov-09-20 08:00AM	Evelo Biosciences Presents New Preclinical Data for Anti-Tumor Effects of Orally Delivered Microbial Extracellular Vesicles at the SITC 35th Anniversary Annual Meeting GlobeNewswire +7.32%
Oct-29-20 07:00AM	Evelo Biosciences Reports Third Quarter 2020 Financial Results and Business Highlights GlobeNewswire
06:30AM	Evelo Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Oct-22-20 04:01PM	Evelo Biosciences to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020 GlobeNewswire
Oct-15-20 07:00AM	Evelo Biosciences to Host Key Opinion Leader Discussion Focused on the Unmet Need in Psoriasis and Atopic Dermatitis and the Potential Opportunity for EDP1815 GlobeNewswire -7.89%
Oct-14-20 07:00AM	Evelo Biosciences Completes Enrollment in Phase 1b Clinical Trial Cohort Evaluating EDP1815 in Atopic Dermatitis GlobeNewswire
Oct-13-20 07:00AM	Evelo Biosciences Treats First Patients in Phase 2 Dose-Ranging Trial of EDP1815 for the Treatment of Psoriasis GlobeNewswire
Oct-12-20 09:00AM	Evelo Biosciences (EVLO) Looks Good: Stock Adds 5.9% in Session Zacks
Sep-14-20 07:06AM	Evelo Biosciences Appoints Julie Carretero as Chief People Officer GlobeNewswire +10.45%
Sep-08-20 07:00AM	Evelo Biosciences to Participate in Upcoming Investor Conferences in September GlobeNewswire +6.95%
Jul-30-20 07:00AM	Evelo Biosciences Reports Second Quarter 2020 Financial Results and Business Highlights GlobeNewswire
Jul-23-20 07:00AM	Evelo Biosciences to Report Second Quarter 2020 Financial Results on Thursday, July 30, 2020 GlobeNewswire -6.31%
Jul-07-20 08:00AM	Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing PR Newswire
Jul-01-20 07:08AM	Evelo Biosciences to Present Clinical Data from Phase 1/2 Trial of EDP1503 at the ESMO World Congress on Gastrointestinal Cancer Virtual Meeting GlobeNewswire
Jun-24-20 07:56PM	Evelo Biosciences Announces Pricing of Public Offering of Common Stock GlobeNewswire
04:01PM	Evelo Biosciences Announces Proposed Public Offering of Common Stock GlobeNewswire
Jun-22-20 02:00AM	Evelo Biosciences Announces EDP1815 to Advance into Phase 2/3 TACTIC-E COVID-19 Trial GlobeNewswire +18.07%
Jun-16-20 07:00AM	Evelo Biosciences to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference GlobeNewswire
May-29-20 12:00PM	Evelo Biosciences, Inc. (EVLO) Upgraded to Strong Buy: What Does It Mean for the Stock? Zacks
May-28-20 08:00AM	Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity PR Newswire -10.42%
07:00AM	Evelo Biosciences to Present at Jefferies Virtual Healthcare Conference GlobeNewswire
May-27-20 12:34PM	Evelo Biosciences, Inc. (EVLO): Hedge Fund Sentiment Unchanged Insider Monkey
11:30AM	Evelo Biosciences Sees Hammer Chart Pattern: Time to Buy? Zacks
May-14-20 02:58PM	Before You Buy Evelo Biosciences, Inc. (NASDAQ:EVLO), Consider Its Volatility Simply Wall St. -5.26%
May-11-20 07:00AM	Evelo Biosciences Reports First Quarter Financial Results and Business Highlights GlobeNewswire +7.87%
May-07-20 07:00AM	Evelo Biosciences, Rutgers University, and Robert Wood Johnson University Hospital Announce Submission of IND for a Phase 2 Study of EDP1815 in COVID-19 Patients GlobeNewswire
May-04-20 09:00AM	Evelo Biosciences to Report First Quarter 2020 Financial Results on Monday, May 11, 2020 GlobeNewswire -8.97%
Apr-15-20 07:00AM	Evelo Biosciences Appoints Neil Graham, M.D., M.B.B.S., M.P.H., as Chief Development Officer GlobeNewswire
Mar-05-20 07:00AM	Evelo Announces Issuance of U.S. Patent Covering Use of Proprietary Bifidobacterium animalis ssp. lactis Strain for Treating Cancer GlobeNewswire -7.35%
Mar-02-20 07:00AM	Evelo Biosciences Announces Biomarker Data Showing EDP1815 is an Orally Delivered Dual Cytokine Inhibitor for Inflammatory Diseases GlobeNewswire
Feb-25-20 12:09PM	Analysts: 3 Healthcare Stocks to Buy on Coronavirus Weakness TipRanks
07:00AM	Evelo Biosciences to Present at 40th Annual Cowen Health Care Conference GlobeNewswire
Feb-13-20 07:00AM	Evelo Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights GlobeNewswire -10.95%
Feb-06-20 08:00AM	Evelo Biosciences to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 13, 2020 GlobeNewswire
Jan-10-20 07:00AM	Evelo Provides Update on Recent Positive EDP1815 Regulatory Interactions on Phase 2 Trial Design Resulting in Shorter Development Timeline to Registration GlobeNewswire
Dec-20-19 06:39PM	Hedge Funds Have Never Been This Bullish On Evelo Biosciences, Inc. (EVLO) Insider Monkey
Dec-19-19 08:00AM	Flagship Unveils Newest Pioneering Platform: Ring Therapeutics PR Newswire +8.92%
Dec-05-19 07:00AM	Evelo Biosciences Appoints Juan Andres to Board of Directors GlobeNewswire
Nov-13-19 08:01AM	Evelo Biosciences to Present at the Stifel 2019 Healthcare Conference GlobeNewswire
Nov-08-19 07:00AM	Evelo Biosciences to Present Preclinical Data from its EDP1503 Oncology Program at the Society for Immunotherapy of Cancers (SITC) Annual Meeting GlobeNewswire
Nov-05-19 07:01AM	Evelo Biosciences Reports Further Positive EDP1815 Interim Clinical Data in Patients with Psoriasis at High Dose in Phase 1b Trial GlobeNewswire
07:00AM	Evelo Biosciences Announces Further Positive Interim Phase 1b Clinical Data in Psoriasis and Reports Third Quarter 2019 Financial Results GlobeNewswire
Oct-29-19 08:00AM	Evelo Biosciences to Host Quarterly Corporate Update Conference Call on Tuesday, November 5th GlobeNewswire
Sep-26-19 04:05PM	Evelo Biosciences to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire
Sep-20-19 07:00AM	Evelo Biosciences to Host Key Opinion Leader Symposium on Unmet Need in Mild to Moderate Psoriasis and Potential for EDP1815 GlobeNewswire
Sep-17-19 07:00AM	Evelo Biosciences Announces the Appointment of David Epstein as Chairman of its Board of Directors GlobeNewswire
Sep-03-19 08:00AM	Evelo Biosciences to Present at the Morgan Stanley 17th Annual Global Healthcare Conference GlobeNewswire
Aug-06-19 10:24PM	Evelo Biosciences, Inc. (EVLO) Q2 2019 Earnings Call Transcript Motley Fool +5.92%
07:01AM	Evelo Biosciences Reports Positive EDP1815 Interim Clinical Data in Psoriasis Patients at Low Dose in Ongoing Phase 1b Trial GlobeNewswire
07:00AM	Evelo Biosciences Announces Positive Interim Phase 1b Clinical Data and Provides Second Quarter 2019 Financial Results GlobeNewswire
Jul-30-19 08:00AM	Evelo Biosciences to Host Quarterly Corporate Update Conference Call on Tuesday, August 6th GlobeNewswire
Jul-25-19 08:00AM	Evelo Biosciences Secures $45 Million Debt Financing from K2 HealthVentures GlobeNewswire -5.46%
Jul-15-19 08:00AM	Kaleido Biosciences Announces Appointment of Theo Melas-Kyriazi to its Board of Directors GlobeNewswire
May-30-19 08:00AM	Evelo Biosciences to Present at Upcoming Investor Conferences in June GlobeNewswire
May-27-19 10:29AM	Introducing Evelo Biosciences (NASDAQ:EVLO), The Stock That Slid 53% In The Last Year Simply Wall St.
May-15-19 08:00AM	Evelo Biosciences to Present at 2019 RBC Capital Markets Global Healthcare Conference GlobeNewswire
May-08-19 02:23PM	In slow year for life science IPOs, this venture firm is making big money American City Business Journals
May-04-19 04:23PM	Evelo Biosciences, Inc. (EVLO) Q1 2019 Earnings Call Transcript Motley Fool
May-02-19 07:00AM	Evelo Biosciences Reports First Quarter 2019 Financial Results and Recent Business Highlights GlobeNewswire
Apr-25-19 07:30AM	Evelo Biosciences to Host Quarterly Corporate Update Conference Call on Thursday, May 2, 2019 GlobeNewswire
Apr-03-19 08:00AM	Evelo Biosciences to Present at 18th Annual Needham Healthcare Conference GlobeNewswire +6.45%
Mar-04-19 07:30AM	Evelo Biosciences to Present at 39th Annual Cowen & Co. Health Care Conference GlobeNewswire
Feb-14-19 07:00AM	Evelo Biosciences Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights GlobeNewswire +9.73%
Feb-07-19 08:00AM	Evelo Biosciences to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, February 14, 2019 GlobeNewswire
Jan-28-19 06:00AM	Evelo Biosciences Announces Dosing of First Patient in Investigator-Sponsored Phase 2a Clinical Trial of EDP1503 in Combination with KEYTRUDA® in Patients with Metastatic Melanoma GlobeNewswire
Jan-04-19 06:00AM	Evelo Biosciences Announces Dosing of First Patient in Phase 1/2 Clinical Trial of EDP1503 in Combination with KEYTRUDA® (pembrolizumab) in Multiple Oncology Indications GlobeNewswire +13.58%
Dec-05-18 08:00AM	Evelo Biosciences to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference GlobeNewswire
Nov-27-18 08:00AM	Evelo Enters into Clinical Trial Collaboration Agreement with Merck GlobeNewswire
Nov-26-18 08:00AM	Evelo Biosciences Announces First Dosing in Phase 1b Clinical Trial of EDP1815 in Psoriasis and Atopic Dermatitis GlobeNewswire +7.21%
Nov-13-18 08:10AM	Report: Developing Opportunities within Evelo Biosciences, ADMA Biologics, Karyopharm Therapeutics, Pingtan Marine Enterprise, Rosetta Stone, and Williams Companies Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-07-18 08:00AM	Evelo Biosciences to Present at Upcoming Investor Conferences in November GlobeNewswire
Nov-01-18 08:00AM	Evelo Biosciences Reports Third Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire +5.05%
Sep-06-18 08:00AM	Evelo Biosciences to Present at the Morgan Stanley 16th Annual Global Healthcare Conference GlobeNewswire
Aug-02-18 08:00AM	Evelo Biosciences Reports Second Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire
Jun-25-18 08:00AM	Evelo Biosciences Added To Russell 3000®, 2000® and Microcap® Indexes GlobeNewswire -5.34%
Jun-15-18 06:28PM	[$$] Verrica Pharma Adds to Drumbeat of Biotech IPOs The Wall Street Journal
Jun-14-18 08:00AM	Evelo Biosciences to Present at the JMP Securities 2018 Life Sciences Conference GlobeNewswire -9.05%
Jun-04-18 08:53AM	Evelo Biosciences' Potential Is 'Significant,' Says Bullish Morgan Stanley Benzinga
May-31-18 08:00AM	Evelo Biosciences Reports First Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire
May-11-18 05:00PM	Evelo Biosciences Announces Closing of Initial Public Offering GlobeNewswire
May-10-18 07:18AM	[$$] Evelo Biosciences Shares Rise Slightly Post-IPO The Wall Street Journal
May-08-18 07:29PM	Evelo Biosciences Announces Pricing of Initial Public Offering GlobeNewswire

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a monoclonal microbial candidate, which is in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of psoriasis or atopic dermatitis. The company is also developing monoclonal microbial candidates, which are in pre-clinical development stage include EDP1815 for treating psoriatic arthritis, rheumatoid arthritis, and axial spondyloarthritis; EDP1867 for asthma; EDP2939 for inflammatory disease; and EDP1632 for neuro-inflammatory diseases. In addition, it is developing EDP1503, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Epstein David R	Director	Dec 11	Buy	6.66	7,700	51,261	17,700	Dec 14 05:15 PM
Liu Xiaoli Jacqueline	Principal Accounting Officer	Dec 01	Sale	5.17	3,000	15,510	0	Dec 02 04:44 PM
Epstein David R	Director	Aug 31	Buy	4.49	5,752	25,804	10,000	Sep 01 04:13 PM
Epstein David R	Director	Aug 28	Buy	4.39	4,248	18,631	4,248	Sep 01 04:13 PM
Flagship Ventures Fund IV Gene	10% Owner	Jun 29	Buy	3.75	4,666,666	17,499,998	4,079,032	Jul 01 05:24 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience